Zebrafish Xenograft Model of Human Lung Cancer for Evaluating Osimertinib Resistance

About half of NSCLC patients with EGFR mutation had secondary mutation T790M after treatment with a first-generation tyrosine kinase inhibitor (TKI), Gefitinib. The third-generation of EGFR-TKI Osimertinib is suitable for patients with EGFR mutation and T790M mutation. However, drug screening for NS...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomed Res Int
Hauptverfasser: Li, Xin-ying, Huang, Li-tang, Wu, Jia-qi, He, Ming-fang, Zhu, Su-hua, Zhan, Ping, Lv, Tang-feng, Song, Yong
Format: Artigo
Sprache:Inglês
Veröffentlicht: Hindawi 2019
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6620834/
https://ncbi.nlm.nih.gov/pubmed/31346515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/3129748
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge